SLC5A2 and obesity disorder: A variety of oral drugs are available for the medical intervention of obesity and obesity-associated nephropathy, such as dipeptidyl peptidase 4 inhibitor (DPP-4), angiotensin-converting enzyme (ACE) inhibitors, GLP-1(Glucagon-like-1) protein receptor agonists, sodium-glucose cotransporter 2 inhibitors (SGLT-2), and statins (5).